The pilot pairs grocery stipends and community health worker support with members who have unmanaged diabetes and unmet social needs.
Commentary|Articles|November 5, 2024
Rethinking Diabetes Care: Are New Therapies Adding Value or Cost?
Author(s)Hayden E. Klein
Sanjula Jain, PhD, chief research officer at Trilliant Health, discusses the rapid adoption of glucagon-like peptide 1 inhibitors for diabetes and preventive care for obesity and late-onset diabetes.
Advertisement
Advertisement
The latest report from Trilliant Health examined both the rapid adoption of glucagon-like peptide 1 (GLP-1) inhibitors for
Related to this article
Posters in an artificial intelligence and digital care session at Kidney Week 2026 spanned CKD risk prediction and LLM-drafted prior authorization letters.
As CKCC nears its sunset, kidney care leaders urge CMS to preserve a dedicated, nephrologist-led accountable care model for advanced kidney disease.
Speakers at ASN Kidney Week urge nephrologists to appeal prior authorization denials, include children in trials, and expand access to glomerular disease therapies globally.
ASN Kidney Week 2026 experts discussed GLP-1 RAs alongside lifestyle care, global access, and bariatric surgery for obesity in chronic kidney disease.
A retrospective study suggests strength exercise may be a safer option than endurance exercise for some people with ACM.
At IDWeek 2026, IDSA and HIVMA leaders and clinician advocates outline how stories, relationships, and bipartisan outreach shape ID and HIV policy.
Insulin icodec-abae becomes the first once-weekly basal insulin cleared for children 10 years and older with type 2 diabetes.
Advertisement
Advertisement